Inspiring to witness the progress and impact of the clinical, research, and innovation communities in improving outcomes for patients with hematological diseases. And hosted in our beautiful home city of Stockholm!
The dynamic hematology treatment landscape of recent years is seeing more and more effective therapeutic options. But with more choice and complexity, a frequent topic of discussion at EHA2026 was:
Which treatment, which order, which patient?
Extended clinical evidence and longer-term outcomes beyond trials will help guide evidence-based decision making. It is our humble privilege as real-world evidence (RWE) researchers to support work addressing such important questions.
Few places capture such high-quality clinical care data than the Nordics, enabling experience to be translated into robust evidence supporting improved outcomes for patients globally.
Ciencia Research’s research experience extends deeply into hematology, including:
- Multiple myeloma
- Chronic lymphocytic leukemia
- Acute myeloid leukemia
- Diffuse large B cell lymphoma
- Follicular lymphoma
- Autoimmune hemolytic anemia
- Sickle cell disease
- Beta thalassemia
How can we support your RWE questions in hematology?
#RealWorldEvidence
#RealWorldData
#Hematology
#NordicHealthData
#EHA2026
